UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers

Schreiberhuber, Lena; Herzog, Chiara; Vavourakis, Charlotte D; Redl, Elisa; Kastner, Christine; Jones, Allison; Evans, Iona; ... Widschwendter, Martin; + view all (2023) The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. International Journal of Cancer , 152 (6) pp. 1269-1274. 10.1002/ijc.34275. Green open access

[thumbnail of Widschwendter_Intl Journal of Cancer - 2022 - Schreiberhuber - The WID‐qEC test  Performance in a hospital‐based cohort and feasibility.pdf]
Preview
Text
Widschwendter_Intl Journal of Cancer - 2022 - Schreiberhuber - The WID‐qEC test Performance in a hospital‐based cohort and feasibility.pdf

Download (679kB) | Preview

Abstract

The majority of endometrial and cervical cancers present with abnormal vaginal bleeding but only a small proportion of women suffering from vaginal bleeding actually have such a cancer. A simple, operator-independent and accurate test to correctly identify women presenting with abnormal bleeding as a consequence of endometrial or cervical cancer is urgently required. We have recently developed and validated the WID-qEC test, which assesses DNA methylation of ZSCAN12 and GYPC via real-time PCR, to triage women with symptoms suggestive of endometrial cancer using ThinPrep-based liquid cytology samples. Here, we investigated whether the WID-qEC test can additionally identify women with cervical cancer. Moreover, we evaluate the test's applicability in a SurePath-based hospital-cohort by comparing its ability to detect endometrial and cervical cancer to cytology. In a set of 23 cervical cancer cases and 28 matched controls the receiver operating characteristic (ROC) area under the curve (AUC) is 0.99 (95% confidence interval [CI]: 0.97-1.00) with a sensitivity and specificity of 100% and 92.9%, respectively. Amongst the hospital-cohort (n = 330), the ROC AUC is 0.99 (95% CI: 0.98-1) with a sensitivity and specificity of 100% and 82.5% for the WID-qEC test, respectively, and 33.3% and 96.9% for cytology (considering PAP IV/V as positive). Our data suggest that the WID-qEC test detects both endometrial and cervical cancer with high accuracy.

Type: Article
Title: The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/ijc.34275
Publisher version: https://doi.org/10.1002/ijc.34275
Language: English
Additional information: © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: DNA methylation, abnormal vaginal bleeding, cervical cancer, early detection, endometrial cancer
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health > Womens Cancer
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery.ucl.ac.uk/id/eprint/10155284
Downloads since deposit
32Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item